FDA Approves Mirikizumab, a Promising Induction and Maintenance Therapy for Ulcerative Colitis

Omvoh (mirikizumab) for Ulcerative Colitis: US FDA Approved Treatment ExplainedПодробнее

Novel Targets and Therapeutic Perspectives in IBD: Beyond Anti-TNFПодробнее

The Evolving Therapeutic Paradigm in IBD: Optimal Positioning of New and Emerging AgentsПодробнее

30초 NEJM 리뷰 ep.5 Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis #shortsПодробнее

Efficacy and safety of mirikizumab in psoriasis: OASIS-1, A. Blauvelt et alПодробнее

FDA approves NEW NOVEL treatments for Ulcerative Colitis | VELSIPITY | OMVOH | Pharmacist ReviewПодробнее

How to Manage Ulcerative Colitis Without MedicationПодробнее

FDA Approves Mirikizumab, a Promising Induction and Maintenance Therapy for Ulcerative ColitisПодробнее

1분 NEJM 리뷰 ep.5 Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisПодробнее

FDA Approves Entyvio for IBD Patients -- IBD in the NewsПодробнее

Improvements in Targeted IBD Management: Innovative Biologics and Small MoleculesПодробнее

Is ReBuilder® FDA Approved?Подробнее

Hope for Ulcerative ColitisПодробнее

FDA approves Rinvoq as first pill to treat moderate-to-severe Crohn's DiseaseПодробнее

COLITIS DIET | What to Eat & Avoid in Ulcerative Colitis-Dr.Rajasekhar M R| Doctors' Circle #shortsПодробнее

Treating IBD: What's Next for Me?Подробнее

Newer therapies on the horizon for Inflammtory Bowel DiseaseПодробнее

FDA Approves Biosimilar to Humira – IBD in the NewsПодробнее